Search

The cumulated effects of climate changes and accelerated urban development, amplified by insufficient funding and/or capacity to implement proactive methods and strategies for monitoring and optimization of water supply systems negatively impact the operation and overall efficiency of these systems, generating considerable problems regarding public comfort and safety and also service costs. Out of all problems, the most tangible issues for the final user are the ones related to the distribution network – the closest system component. In order to address these problems, an integrated analysis of the conditions of each urban area is required, accounting for actual water demand, pressure requirements, network configuration, power consumption and development forecasts. This article presents the set of measures proposed for optimisation of the distribution network of Babadag Town from Romania, consisting of changes intended to improve the hydraulic capacity of the network and also on reducing the water loss based on water balance evaluation and hydraulic modelling of existing and proposed network configurations.

Nowadays the corporate sector is a prominent stakeholder in the sustainability field. Companies across the world are starting to look at more environmentally friendly business practices, largely because of the urgent climate situation and because of the highest demand for these practices from the market. Furthermore, sustainability disclosure, formerly entirely optional, has progressively become required in several nations during the past years, especially in the European Union and among businesses and production sectors. Plus, the Non-Financial Reporting Directive (NFRD), which requires certain major corporations with EU headquarters to provide sustainability data, was adopted by the European Parliament in 2014. Later, additional regulatory actions have been taken, and in 2021 the European Commission has launched a new political agreement on the Corporate Sustainability Reporting Directive (CSRD), to respond to the growing criticism regarding the reporting criteria, while increasing the reporting obligations’ level of detail. The given paper is focused on the analysis of the processes of sustainability of Romanian and European companies, more exactly about the most common CSR practices of companies. This paper aims to provide further implications for policymakers, students and researchers whilst promoting sustainability and being of use to business leaders.

Aims: Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results: We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 ± 13.9 vs. 60.2 ± 7.3 years, P = 0.0001), and significantly different in terms of NT‐proBNP [ATTR: 1472.5 ng/L (97–4218.5) vs. AL 8024 ng/L (3058–14 069) P = 0.001], hs‐cTn I [ATTR: 10 ng/L (4–20) vs. AL 78 ng/L (32–240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8–105.3) vs. AL: 68.4 mL/min (47.8–87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: −13.1% ± 3.5 vs. AL: −9.1% ± 4.3 P = 0.04), RV strain (ATTR: −21.9% ± 6.2 vs. AL: −16.8% ± 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% ± 12 vs. AL: 13.6% ± 7.8 P = 0.02). Cut‐off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT‐proBNP AUC 0.799; hs‐cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%. Conclusions: CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non‐invasive checkpoints, which can be useful in guiding the decision‐making process towards a more accurate and rapid differential diagnosis. [ABSTRACT FROM AUTHOR]

Background/Objectives: Graft-versus-host disease (GVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) resulting from histocompatibility differences between donor and host cells leading to inflammation, tissue damage, and compromised patient outcome. Extracorporeal photopheresis (ECP) is considered as a second-line treatment administered to patients with GVHD who do not respond to corticosteroid treatment or who experience a relapse after an initial response and are therefore classified as steroid refractory (SR). The aim of this study is to evaluate the clinical response rates in both pediatric and adult patients with acute (a) or chronic (c) GVHD and to assess the effectiveness of ECP using the real-world data from a single center. Methods: We performed a retrospective study on 30 patients, including 11 pediatric and 19 adult patients who were treated with ECP as a second-, third-, or fourth-line therapy for (a) and (c) GVHD, alongside corticosteroids and other immunomodulatory medications. The median time from aGVHD onset to ECP was 11.5 days (range: 3 days–9 months), while for cGVHD, the median time was 90 days (range: 2 days–9 months). Results: The overall response rate (ORR) in the aGVHD patient population was 60% with a median of 9 procedures (range: 2–20). For cGVHD patients, the ORR was 70% after a median of 23.5 ECP procedures (range: 8–43). Most patients had skin involvement, with ECP achieving an ORR of 81.8% in aGVHD and 77.7% in cGVHD cases. Conclusions: ECP is a beneficial therapy for patients with (a) and (c) GVHD who have not responded to corticosteroids and other forms of immunosuppressive therapy. Specifically, ECP demonstrated efficacy in improving skin and oral symptoms and permitted reductions in or the elimination of their corticosteroid usage. The study found that extending the duration of ECP treatment was associated with better outcomes, and no detectable complications were observed over a 38-week period. [ABSTRACT FROM AUTHOR]

We present the case of a 66 year-old male patient who developed severe postoperative thrombocytopenia after revision total hip arthroplasty. The patient underwent surgery in a dedicated orthopedics hospital and was initially managed in the intensive care unit. Upon the development of thrombocytopenia, he was referred to a dedicated hematology clinic for investigation and advanced management. A thorough diagnostic algorithm was employed in order to rule out the main causes of thrombocytopenia. By exclusion, we diagnosed the patient as suffering from a rare and severe form of postoperative thrombocytopenia through an immune mechanism. Although postoperative thrombocytopenia is relatively frequent but transitory and no treatment is required, this condition was refractory to corticosteroids and substitution therapy; however, it quickly responded to treatment with thrombopoietin receptor agonists. The patient recovered and was successfully discharged with normal platelet values. While rare occurrences, alternative causes of thrombocytopenia such as infection, drug-induced, or immune should be considered in patients developing postoperative thrombocytopenia. [ABSTRACT FROM AUTHOR]

Abstract Cardiac amyloidosis is a restrictive cardiomyopathy determined by the accumulation of amyloid, which is represented by misfolded protein fragments in the cardiac extracellular space. The main classification of systemic amyloidosis is determined by the amyloid precursor proteins causing a very heterogeneous disease spectrum, but the main types of amyloidosis involving the heart are light chain (AL) and transthyretin amyloidosis (ATTR). AL, in which the amyloid precursor is represented by misfolded immunoglobulin light chains, can involve almost any system carrying the worst prognosis among amyloidosis patients. This has however dramatically improved in the last few years with the increased usage of the novel therapies such as proteasome inhibitors and haematopoietic cell transplantation, in the case of timely diagnosis and initiation of treatment. The treatment for AL is directed by the haematologist working closely with the cardiologist when there is a significant cardiac involvement. Transthyretin (TTR) is a protein that is produced by the liver and is involved in the transportation of thyroid hormones, especially thyroxine and retinol binding protein. ATTR results from the accumulation of transthyretin amyloid in the extracellular space of different organs and systems, especially the heart and the nervous system. Specific therapies for ATTR act at various levels of TTR, from synthesis to deposition: TTR tetramer stabilization, oligomer aggregation inhibition, genetic therapy, amyloid fibre degradation, antiserum amyloid P antibodies, and antiserum TTR antibodies. Treatment of systemic amyloidosis has dramatically evolved over the last few years in both AL and ATTR, improving disease prognosis. Moreover, recent studies revealed that timely treatment can lead to an improvement in clinical status and in a regression of amyloid myocardial infiltration showed by imaging, especially by cardiac magnetic resonance, in both AL and ATTR. However, treating cardiac amyloidosis is a complex task due to the frequent association between systemic congestion and low blood pressure, thrombo‐embolic and haemorrhagic risk balance, patient frailty, and generally poor prognosis. The aim of this review is to describe the current state of knowledge regarding cardiac amyloidosis therapy in this constantly evolving field, classified as treatment of the cardiac complications of amyloidosis (heart failure, rhythm and conduction disturbances, and thrombo‐embolic risk) and the disease‐modifying therapy.

Introduction. The prognosis of pediatric solid tumors has improved in recent years through the use of multimodal treatment – chemotherapy, local control (surgery and radiotherapy) and hematopoietic stem cell transplantation (HSCT) for high-risk forms. A limiting factor of these transplant procedures is short-term toxicity, oral mucositis (OM) being associated with potential severe evolution. The introduction of tandem stem cell transplant procedures, which increase the intensity of chemotherapy treatment and thus increase the response rate, is associated with increased toxicity. In this study we evaluated the impact of multiple transplant procedures on the severity and evolution of OM. Materials and methods. This retrospective study included 57 pediatric patients diagnosed with solid tumors (neuroblastoma, germ cell tumor, Ewing sarcoma, nephroblastoma) who underwent HSCT in the Pediatric Bone Marrow Transplantation Unit of Fundeni Clinical Institute, between January 2002 and December 2020. Patients were divided into 2 study groups: the first group included patients who had one HSCT procedure (43 patients) and the second group included patients who benefited from multiple HSCT procedures (14 patients). We evaluated the degree and average extent of OM, associated risk factors, duration of analgesic treatment and parenteral nutrition, as well as infectious risk. Conditioning regimens were based on administration of busulfan, thiotepa or ifosfamide. All patients received prophylactic antimicrobial therapy and followed a daily oral care protocol. Results. The 57 patients underwent 73 HSCT procedures for the following diagnoses: 36 neuroblastoma, 6 germinal cell tumor, 12 Ewing sarcoma and 3 Wilms tumor. Patients were diagnosed, staged and treated according to international protocols. The study highlights the influence on the degree of OM: delayed platelet engraftment and increased parenteral nutrition requirements correlated with the number of HSCT procedures per patient. Infectious risk was higher for patients from the second study group. Conclusions. OM treatment remains prevention-centered and identifying effective measures, encouraging modern treatment strategies and developing practical evidence-based guidelines are imperative.

Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer, with 80–85% represented by B cell ALL and only 15% by T cell ALL. T Cell ALL (T-ALL) carries a more reserved prognosis compared to B Cell ALL (B-ALL) with regard to response to treatment, risk of relapse, and overall survival. Progress made in current monitoring protocols such as via flow cytometry immunophenotyping (FCM) and by PCR-based amplification of antigen-receptor genes led to improved management of patients with ALL and superior rates of survival. Nevertheless, challenges remain in some clinical cases. This manuscript describes a unique case of T-ALL and raises awareness of such clinical challenges. The article presents an overview of the flow cytometry immunophenotyping at diagnosis and during treatment of a pediatric patient with T-ALL from Fundeni Clinical Institute. In this case, in spite of various therapeutic measures such as first-line chemotherapy for high risk group, salvage chemotherapy (FLAG), conditioning regimen (FLU-BU-TT-ATG), and stem cell transplant, a chemoresistance clone continued to be present.

Abstract Background In Romania, 23 patients have been diagnosed with hereditary transthyretin amyloidosis (ATTRh), 18 of whom have the Glu54Gln mutation. This retrospective cohort included all patients with Glu54Gln-mutated ATTRh who were diagnosed in Romania from 2005 to 2018. Results Of 18 patients, 10 were symptomatic, five were asymptomatic carriers and three died during the study. All originated from North-East Romania. Median age at symptom onset was 45 years; median age at death was 51 years. All patients had cardiac involvement, including changes in biomarkers (mean N-terminal-pro B-type natriuretic peptide: 2815.6 pg/ml), electrocardiography (15% atrial fibrillation, 38% atrioventricular block, 31% right bundle block), and echocardiography (mean interventricular septum: 16 mm, mean left ventricular ejection fraction: 49%). Scintigraphy showed myocardial radiotracer uptake in all patients. In addition, 92% of patients had polyneuropathy at diagnosis and 53% had carpal tunnel syndrome; 69% exhibited orthostatic hypotension and 31% suffered from diarrhea. No renal or liver involvement was observed. Conclusions This is the largest Glu54Gln-mutated ATTRh cohort diagnosed to date, and to our knowledge the first describing this variant worldwide. Clinical features of this variant are early onset, neurological and cardiac involvement, aggressive disease progression and short survival. Early diagnosis and therapeutic intervention have potential to improve prognosis in ATTRh.

Managerial orientation has become a key concept regarding SMEs internationalization even if not all companies have enough experience in this complex process. During the last decades, traditional internationalization practices (exporting), broadened and developed into a multi-faceted and more differentiated activity that enhances the competitiveness of a business. This paper's objective is to present how and if the international activity of a business and its environment are influenced by management strategic decisions. By analyzing the successful internationalization of Romanian cases, this paper aims to establish a connection between certain managerial approaches and the success of the business (risks taken, capabilities, and process in general). The study was conducted over three months, where we collected data using a combination of instruments and methods (such as. surveys, interviews, analysis of data, and online research about the companies). Effective management practices are crucial for the success of SMEs seeking to internationalize. The role of high-quality management and a manager's education can contribute to the company's overall success and its benefits. [ABSTRACT FROM AUTHOR]

Introduction. Down syndrome (DS) is an important medical problem because it is one of the most frequent genetic diseases in children despite thorough neonatal screening, with an incidence of approximately 1:10 to 1.000 live births worldwide (1,3,4). An essential aspect is that patients with DS have a 10-15 higher risk than the general paediatric population to develop malignant hemopathy, 20-30% develop acute leukaemia (AL) (5). Recent studies reveal a good response of AL to chemotherapy in patients with DS, mortality is due to multiple complications associated with associated morbidity, which makes the management of these pathologies a real challenge especially in adapting chemotherapy, which has determined the interest for the clinic's caseload analysis. We conducted an 8-year study at the Paediatric Department of Fundeni Clinical Institute of Bucharest, Romania. Objectives. Analysis of the particular diagnostic and therapeutic aspects of patients with DS and acute leukaemia (AL), ALL and AML, on the records of the Paediatric department of Fundeni Clinical Institute during 2010-2018. Material and method. The retrospective, observational, analytical study monitored the cohort from the following points of view: incidence, epidemiology, age at diagnosis, AL type, clinical symptoms at onset, survival rate, overall mortality, treatment related mortality (TRM), identification of relapse and the complex therapeutic attitude of both the underlying pathology and of leukaemia with the assessment of the response rate to chemotherapy. Conclusions. The complex approach of DS-associated hematologic pathology led to an increased percentage of complete remission, 91.6%, without identifying any relapse during the study. Low values of overall survival rate over 8 years and EFS at 3 years = 50% demonstrates an increased mortality rate during the chemotherapy due to the complications generated by this one (TRM 41.6%), which demonstrates the difficulty of managing such a child with two serious diseases, DS and AL. The DS-specific genetic profile produces increased sensitivity to chemotherapy toxicity and multiple organic impairment, which increases the morbidity and mortality rate in these patients, regardless the mortality due to malign hemopathy.

Introducere. Leucemia acută limfoblastică (LAL) este cea mai frecventă formă de cancer în populaţia pediatrică (1). Datorită ajustării continue a protocoalelor terapeutice, rata de supravieţuire a crescut în ultimii ani (2). În ciuda tuturor eforturilor depuse, rata mortalităţii date de complicaţii (TRM = treatment related mortality) se situează în jur de 2-4% în ţările vest-europene (3,4). Materiale şi metode. Studiul este unul analitic, observaţional, retrospectiv, de tip cohortă, primul de acest tip în Romania, efectuat într-un singur centru hematologic pediatric, Clinica IC Fundeni, în perioada 2014-2017. Acesta evaluează incidenţa mortalităţii globale, incidenţa mortalităţii date de orice cauză, alta decât progresia bolii (NRM = Non Relapse Mortality) şi principala cauză a decesului la copii diagnosticaţi cu LAL. Rezultate. Am inclus 142 pacienţi diagnosticaţi în perioada ianuarie 2014-iunie 2017, cu monitorizare pe parcursul a 48 de luni post diagnostic. Mortalitatea globală a cohortei este 10,5% (15/142). Rata mortalităţii data de NRM este 7,04% (10/15). Aceşti 10 pacienţi aflaţi în remisiune moleculară au drept principală cauză a decesului infecţia precipitată de complicaţiile apărute pe parcursul tratamentului (TRM = treatment related mortality cu/fără IRM = infection related mortality). Studiul a evidenţiat procente crescute de IRM, 6,3%, peste valoarea decelată de alte studii, ceea ce explică şi creşterea valorii de NRM şi cea a mortalităţii globale, în contrast cu valorile TRM 2,1%, aceasta fiind în intervalul de referinţă (12,17,19,20). Cea mai frecventă cauză de NRM a fost infecţia cu Clostridium difficile (4/10). Concluzie. Sunt importante de reţinut procentul mare de obţinere a remisiunii complete (98%) şi supravieţuirea globală impresionantă la 4 ani (89,4%).

Introduction. Acute lymphoblastic leukemia (ALL) is the most common form of cancer in the pediatric population (1). The survival rate has increased in recent years due to the continuous adjustment of therapeutic protocols (2). Despite all the efforts made alongside the evolution of new therapeutic protocols, the treatment related mortality (TRM) is around 2-4% in the Western European countries (3,4). Materials and methods. This retrospective is an analytical, observational and cohort-type study, the first of this kind in Romania, performed in a single pediatric hematology center, Clinical Institute Fundeni, between 2014 and 2017. It assesses the incidence of global mortality, the incidence of mortality due to any cause other than progression of disease (NRM = Non Relapse Mortality) and the main cause of death in children diagnosed with ALL. Results. We included 142 patients diagnosed between January 2014 and June 2017, with follow-up of 48 months post-diagnosis. The overall mortality of the cohort is 10.5% (15/142). The mortality rate for any other cause except disease progression (NRM) is 7.04% (10/15). These ten patients, in molecular remission, have as main cause of death complications that occurred during treatment (TRM= treatment related mortality with / without IRM = infection related mortality). The study showed increased percentages of IRM 6.3%, over value of other studies, explaining and increasing also the value of NRM and also the value of global mortality; In contrast to TRM 2.1%, this being in the reference range (12,17,19,20). The most common cause of NRM was Clostridium difficile infection (4/10). Conclusion. There are important to note the high percentage of achievement of complete remission (98%) and impressive global survival at 4 years (89.4%).

Introduction: Childhood acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the acquisition of several genetic lesions in the lymphoid progenitors with subsequent proliferation advantage and lack of maturation. Along the years, it has been repeatedly shown that minimal residual disease (MRD) plays an important role in prognosis and therapy choice. The aim of the current study was to determine the prognostic role of MRD in childhood ALL patients in conjunction with other relevant patient and disease characteristics, thus showing the real-life scenario of childhood ALL.Patients and Methods: The retrospective study includes childhood ALL patients that were treated according to the BFM ALL IC 2009 between January 2016 and December 2018 at the Fundeni Clinical Institute, Bucharest, Romania.Results: None of the variables significantly influenced the induction-related death in our study. None of the variables independently predicted relapse-free survival (RFS) with the highest tendency for statistical significance being represented by poor prednisone response. Non-relapse mortality (NRM) was independently predicted by age, prednisone response, and day 33 flow cytometry-MRD (FCM-MRD). Overall survival (OS) was independently predicted by prednisone response and day 33 FCM-MRD. Event-free survival (EFS) was independently predicted by age, prednisone response, and day 33 FCM-MRD.Conclusion : Prednisone response, day 15 FCM-MRD, day 33 FCM-MRD, and the risk group represent the most important factors that in the current study independently predict childhood ALL prognosis.

Background: Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative neoplasm diagnosed in young children, characterized by somatic or germline mutations that lead to hyperactive RAS signaling. The only curative option is hematopoietic stem cell transplantation (HSCT). Recent data showing that aberrant DNA methylation plays a significant role in pathogenesis and correlates with clinical risk suggest a possible benefit of hypomethylating agents (HMA) in JMML treatment.Aim: The aim is to report the results of HMA-based therapy with 5-azacytidine (AZA) in three JMML patients treated in a single center, non-participating in EWOG-MDS study.Methods: The diagnosis and treatment response were evaluated according to international consensus criteria. AZA 75 mg/m2 intravenous (i.v.) was administered once daily on days 1–7 of each 28-day cycle. All patients were monitored for hematologic response, spleen size, and evolution of extramedullary disease. Targeted next generation sequencing (NGS) were performed after the 3rd AZA cycle and before SCT to evaluate the molecular alterations and genetic response.Results: Three patients diagnosed with JMML were treated with AZA (off-label indication) in Pediatric Department of Fundeni Clinical Institute, Bucharest, Romania between 2017 and 2019. There were two females and one male with median age 11 months, range 2–16 months. The cytogenetic analysis showed normal karyotype in all patients. Molecular analysis confirmed KRAS G13D mutation in two patients and NRAS G12D mutation in one patient. The clinical evaluation showed important splenomegaly and hepatomegaly in all 3 pts. One patient received AZA for early relapse after haploidentical HSCT and the other two patients received upfront AZA, as bridging therapy before HSCT. After HMA therapy, 2/3 patients achieved clinical partial response (cPR), 1/3 had clinical stable disease (cSD) and all had genetic stable disease (gSD) after 3 cycles and were able to receive the planned HSTC. One patient achieved clinical and genetic complete response before HSCT. During 22 cycles of AZA there were only four adverse events but only one determined dose reduction and treatment delay.Conclusion: Our data show that AZA monotherapy is safe and effective in controlling disease both in upfront and relapsed patients in order to proceed to HSCT.

Copyright of Farmacia is the property of Societatea de Stiinte Farmaceutice Romania and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Understanding how businesses can improve in a sustainable environment has an increasingly significant role in the economic context and its growth. Nowadays, sustainable companies are constantly reducing the pressure of law, diminishing the costs of utilities, and cultivating a culture inside the working context. More than 90% of CEOs of environmental companies acknowledge that sustainability represents essential business market growth. Green businesses prioritize sustainability and social responsibility in their operations and environmental business practices, as they aim to conserve the natural environment and promote green practices while ensuring high levels of profitability and reducing the carbon footprint. Unfortunately, over time companies have faced significant barriers such as affording green investments and the costs implied or analysing the market demand, due to not all the systems and governments aligning with the emergent models of a green economy. The public sector should however play an important role when considering sustainability by promoting green operations and policies, applying regulatory alternatives, and providing more concrete incentives for green businesses. Nowadays, green enterprises have grown in importance in the economic environment cultivating more shared green values. Therefore, promoting green entrepreneurship among all segments of society is a focus both at the policy level and inside the business culture. This paper aims to define concepts of economic growth and sustainable development around the business context and to understand how sustainable companies relate to the 3 E's of the green economy, as these appear to determine business longevity and help maintain a positive business reputation among other businesses. [ABSTRACT FROM AUTHOR]

Artificial insemination is the most important reproductive biotechnology that helps to increase the genetic value of animals on a farm. It enables the rapid and massive diffusion of desired traits by using the semen of selected males with high productive potential. Correlating types of timing and oestrus induction in sheep with long-term semen preservation (cryopreservation) is the best way to increase productivity and ensure the dissemination of genetic progress. The aim of the present research was to identify the most effective treatment option for the application of artificial insemination in Merino Palas sheep, with frozen semen, in the normal breeding season. By using prostaglandins (Roflavol) for synchronizing females and identifying the optimal moment for performing artificial insemination, a calving rate of 32.14% was obtained with a prolificacy of 111.11%, and by applying the hormonal treatment Chronogest- Folligon to induce and synchronize oestrus with fixed point artificial insemination, the calving rate was 53.33% and the prolificacy was 131.25%. By artificial inseminating the ewes detected in natural oestrus with test rams’ frozen semen, a calving rate of 31.67% and prolificacy of 110.53% was obtained. [ABSTRACT FROM AUTHOR]

The environmental economy and green transition are closely related concepts that focus on promoting new sustainable paths and economic growth and reducing the negative impact of activities on the environment. Therefore, the environmental economy and green transition have become two of the most important directions in the continuing development of the world. The environmental economy involves the ongoing progress of green technologies, green energy, and different activities aimed at changing society's attitude toward more environmental solutions and policies. The environmental economy is a discipline that studies the economic effects of environmental products, services and policies in different realities, economies, and societies. It includes goods and services that help to preserve the stock of natural resources and protect the environment. The green transition refers to the process of transforming people, planet, and partnerships to an environmentally friendly economy. This includes also implementing policies and practices that reduce greenhouse gas emissions, promote energy efficiency, increase the use of renewable energy sources, and reduce waste and pollution. The aim of this paper is to analyze, based on Eurostat data, the evolution of the environmental economy for the EU Member States, considering that the topic has nowadays prompted both governments and corporations to make commitments and place increasing emphasis towards protecting the environment and promoting a sustainable economic development through various programs or regulations. Additionally, this article is also aiming to observe the influence of the environmental economy on exports across the EU and understanding the process of having a green transition. [ABSTRACT FROM AUTHOR]